XBiotech Inc. (XBIT) stock
Close on Nov 11, 2026Market cap $59.45MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $59.45M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.48
- Dividend yield
- –
- Free cash flow yield
- -68.97%
Fundamentals
- Net income
- -$43.59M
- EPS, diluted
- -$1.43
- Free cash flow
- -$41.00M
- Book value per share
- $4.07
- Diluted shares
- 30M
Trading
- Previous close
- $1.97
- Open
- $1.97
- Day's range
- $1.95 – $1.98
- Volume
- 18,552
- Average volume (20 days)
- 92,175
- Beta (5 years)
- 1.11
- 52-week range
- $1.80 – $3.44
- RSI (14 days)
- 45.3
- Volatility (1 year)
- 42.8%
- Relative volume
- 0.35×
- WACC
- 10.5%
On 3 of our idea lists: Net-nets, More cash than they're worth, Insiders buying the dip
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | XBIT | S&P 500 | Difference | XBIT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.8% | -2.4% | −12.4 pts | ||
| 3 months | -16.3% | -1.2% | −15.2 pts | ||
| Year to date | -18.4% | +12.3% | −30.7 pts | ||
| 1 year | -33.7% | +12.4% | −46.1 pts | ||
| 3 years | -50.5% | +78.8% | −129.3 pts | -20.9% | +21.4% |
| 5 years | -87.2% | +75.2% | −162.4 pts | -33.7% | +11.9% |
| 10 years | -83.6% | +311.1% | −394.7 pts | -16.5% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases XBiotech filed with the SEC as exhibits to Form 8-K or 6-K
About XBiotech
Pharmaceutical Preparations
XBiotech Inc. is a biopharmaceutical company focused on discovering and developing True Human monoclonal antibodies to treat various diseases. These antibodies are sourced from human donors exhibiting natural immune responses rather than through animal engineering methods. The company focuses on developing antibody therapies that neutralize interleukin-1 alpha, a protein involved in inflammatory tissue breakdown, trauma response, and disease processes. Its clinical and research pipeline includes candidates for conditions in oncology, rheumatology, neurology, and infectious diseases such as methicillin-resistant Staphylococcus aureus, shingles, influenza, and Clostridioides difficile.
Company profile, executives and historyXBiotech stock: common questions
What is XBiotech's stock price?
XBIT closed at $1.95 on Nov 11, 2026, down 1.02% on the day. Over the past 52 weeks it traded between $1.80 and $3.44.
What is XBiotech's market cap?
XBiotech was worth $59.45M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is XBIT's P/E ratio?
XBiotech lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.43), so it has no meaningful P/E ratio.
Does XBiotech pay a dividend?
No. XBiotech has not paid a cash dividend over the last twelve months.
How has XBIT stock performed over the past year?
Including dividends, XBIT returned -33.7% over the past year, against +12.4% for the S&P 500.
How many XBIT shares are sold short?
0M shares were sold short at the latest FINRA report, 1.30% of the float, or 2.6 days of average trading volume.
Who are XBiotech's competitors?
Companies most similar to XBiotech by business, industry and size include SYRE, IBIO, XNCR, ABCL, JBIO.
See a number that looks wrong?